Voyager Therapeutics has expanded its Alzheimer’s disease pipeline with a new gene therapy program targeting APOE, the strongest genetic risk factor for Alzheimer’s. The program utilizes Voyager’s proprietary intravenous (IV) TRACER capsid to deliver a bifunctional payload designed to silence the high-risk APOE4 variant while simultaneously introducing the protective APOE2 variant. This approach aims to maintain overall APOE levels while shifting the balance towards a less detrimental form.
This development represents a significant advancement in Alzheimer’s research. Targeting APOE directly addresses a core genetic vulnerability for the disease, offering a potential preventative strategy for high-risk individuals. The IV delivery method, enabled by the TRACER capsid technology, is a critical aspect, as it bypasses the need for invasive brain injections, potentially making the therapy accessible to a wider patient population. This approach could change how Alzheimer’s is treated, moving beyond symptom management towards addressing the underlying genetic cause.
Preclinical studies in APOE4 knock-in mice demonstrated significant reduction of APOE4 in relevant brain regions and a concurrent increase in APOE2 after a single IV injection. Voyager plans to present early data from this program at a scientific meeting in 2025. The company’s Alzheimer’s franchise now includes four wholly-owned assets: VY7523, a clinical-stage anti-tau antibody; VY1706, an IV-delivered tau silencing gene therapy; a vectorized anti-Aβ antibody gene therapy; and this new APOE gene therapy program.
This new program strengthens Voyager’s position in the Alzheimer’s field, showcasing their commitment to developing multiple therapeutic approaches against key Alzheimer’s targets (tau, amyloid, and APOE). The potential of a single IV administration to modify a core genetic risk factor for Alzheimer’s is a groundbreaking step that could significantly impact the future of Alzheimer’s prevention and treatment. The anticipated data release in 2025 will be a critical milestone for the program and the field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
